N/A
Loading page data
Please wait a moment
Loading page data
Please wait a moment
Second Floor, 150 Fleet Street,
London, EC4A 2DQ.
+44 203-837-5656
108 W 39th Street, Ste 1006,
PMB2219, New York, NY 10018
+1 646-878-6329
IT Unit No. 504, 5th Floor, Icon
Tower, Baner, Pune - 411045.
+91 906 779 3500
Peoples who is having asthma are prescribed with a long-acting bronchodilators as an additional treatment. Long-acting bronchodilators help keep your airways open by relaxing the muscles around your airways.
To prevent various asthmatic symptoms, long-acting bronchodilators are prescribed in addition to regular steroid preventer treatment and Several deaths have occurred in low and middle-income nations due to high air pollution caused by industrial smoke, dust, mold spores, pollen, volcanoes and wildfires.
Outdoor pollution, as well as pollution from dust and chemicals, is responsible for various respiratory infections and Chronic Obstructive Pulmonary Disease (COPD). According to global asthma report 2018, 339 million peoples are affected by asthma and around 1000 peoples are dying every day due asthmatic attack.
An increasing number of people who are suffering from COPD asthma and are behind the growth of long-acting bronchodilators market. The government is also supporting the growth of the global Long-acting Bronchodilators market by increasing awareness among the population through patient education program.
Other factor which is responsible for steady growth of long-acting bronchodilators market is key drugs which are at the later stage in the pipeline from major key players like AstraZeneca and Sanofi.
Major key players involved in the long-acting bronchodilators market are trying to develop a new forms of drug administration which is expected to increase the intake of drugs and drive the growth of global Long-acting Bronchodilators market.
Players within Long-acting Bronchodilators market are investing expansively for the development of different kinds of nebulizers and inhalers which will increases effective administration of Long-acting bronchodilators an increased patient compliances.
New advanced technology like Ultrasonic nebulizers is proved more efficient as compared to jet nebulizers that are already available in markets today. Another important factor which is driving the global long-acting bronchodilators market is the use of electronic system technology such as electronic health records.
On the contrary, some studies have identified the tolerance for Long-acting Bronchodilators and it is not recommended to use as a monotherapy for treatment in asthma. While administering by inhalation root there is a serious toxicity observed due to propellants.
Newly developing monoclonal antibodies are having greater advantages over Long-acting Bronchodilators and this all factors will be the major threat in long-acting bronchodilators market growth.
Teva Pharmaceutical Industries Ltd, Novartis AG, Abbott Laboratories, Boehringer Ingelheim GmbH, Merck & Co., Inc., AstraZeneca plc, GlaxoSmithKline plc., Vectura Group plc, F. Hoffmann-La Roche AG, Pfizer Inc. and others.
